The resulting strategy families correspond to major design objectives: improving pharmacokinetics and biodistribution [33, 37, 53, 66, 67], modulating vascular access and perfusion [11, 12, 15, 68, 69], normalizing or reprogramming stromal barriers [13, 17, 30, 32, 34, 70], enabling endogenous TME-responsive release or activation [46,47,48], reshaping antitumor immunity [29, 35, 71], and integrating imaging with therapeutic intervention [72,73,74]
The HormoneSynergy and RetzlerRx Perspective At HormoneSynergy, we consider both liposomal and S-acetyl glutathione legitimate formulation strategies
Forcina GC, Dixon SJ
A GHRH analog (like CJC-1295 or Tesamorelin) tells the pituitary to make and get ready to release more GH it primes the tank